Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04583982 · ClinicalTrials.gov registry record
ImmuneSense™ COVID-19 Study
A clinical trial, sponsored by Adaptive Biotechnologies.
- Completed
- Registry status
- 180
- Enrollment target
NCT04583982 is a clinical trial that has completed, run by Adaptive Biotechnologies. The registered enrollment target is 180 participants.
The verdict
NCT04583982 has completed, sponsored by Adaptive Biotechnologies.
- COMPLETED
- Registry status
- 180 participants
- Enrollment target
Study Summary
Coronavirus disease is of an urgent global priority. The purpose of ImmuneSense™ COVID-19 study is to evaluate the clinical performance and to provide data for clinical validation for the T-Detect™ SARS-CoV-2 (previously referred to as immunoSEQ Dx SARS-CoV-2) Assay in support of Adaptive's Emergency Use Authorization (EUA) request for T-Detect™ SARS-CoV-2 and secondary aims. This assay is intended to detect immune response to the virus that causes coronavirus disease (COVID-19), SARS-CoV-2. This is critically important because the immune system may be able to tell us important information about how our own bodies detect and respond to the disease that current tests cannot.
Interventions
- OTHER T-Detect™ SARS-CoV-2 Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2020-10-09 |
| Est. Completion | 2020-12-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04583982
The ClinicalTrials.gov registry entry for NCT04583982 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adaptive Biotechnologies, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which T-Detect™ SARS-CoV-2 Assay is the first listed.
NCT04583982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04583982 about?
NCT04583982 is a clinical study titled "ImmuneSense™ COVID-19 Study". Coronavirus disease is of an urgent global priority. The purpose of ImmuneSense™ COVID-19 study is to evaluate the clinical performance and to provide data for clinical validation for the T-Detect™ SARS-CoV-2 (previously referred to as immunoSEQ Dx SARS-CoV-2) Assay in support of Adaptive's Emergenc...
What is the current status of trial NCT04583982?
This trial is currently completed. The enrollment target is 180 participants. The study started on 2020-10-09. Estimated completion is 2020-12-04.
What interventions are being tested in trial NCT04583982?
The interventions under investigation include: T-Detect™ SARS-CoV-2 Assay (OTHER).
Who is sponsoring clinical trial NCT04583982?
This trial is sponsored by Adaptive Biotechnologies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.